Congenital CMV infection causes serious neurodevelopmental sequelae, including mental retardation, cerebral palsy, and sensorineural hearing loss
This way, they can get the most from their treatment while staying safe
[CrossRef] [Google Scholar] Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders
Our clinical trial program gives us strong confidence in how Foundayo will perform in the real world, which is what ultimately matters
Mol Metab (2014) 3(3):24151
At the March committee meeting, Kinsley said the cost to the state for GLP-1 coverage would be "is in the range of zero to 10 million in state dollars, which is much cheaper than a lot of the costs of cardiovascular disease." According to the NCDHHS statement, which was issued to WUNC on Thursday, "...the current estimate to cover GLP-1s is approximately $16 million annually